Glioblastoma model mouse rescue from mortality by brain-targeted catalytically-enhanced angiotensin-converting enzyme 2 mutant-antibody fusion protein

ACE2dm-s1, an ACE2-brain-targeted antibody fusion, improves survival in CT-2A xenograft glioblastoma model mice when combined with a STING agonist, unlike losartan.

• Why it matters: Glioblastoma therapy needs tumor microenvironment modulation, and prior RAS-axis targeting with losartan failed to improve survival in the same CT-2A combination setting.
• What they did: Mice bearing CT-2A xenografts received ACE2dm-s1 plus a small-molecule STING agonist, and flow cytometry assessed brain immune-cell population shifts after treatment.
• The result: The combination increased survival only with ACE2dm-s1, and immune profiling showed an ACE2dm-s1-driven shift toward an anti-tumoral brain composition, supporting its use as a TME adjuvant.

AI summary of the abstract · may contain errors · not medical advice · read the paper.